PURPOSE OF REVIEW: This review summarizes recent advances in the role of endogenous and exogenous Toll-like receptor ligands in the activation and inhibition of immune responses in transplantation. RECENT FINDINGS: During an alloresponse, Toll-like receptors can be engaged by both damage-induced endogenous ligands or microbial-associated molecular patterns. The damage-induced molecule high mobility group box 1 protein and its binding to Toll-like receptor 4 have been identified as major initiators of antitumor and antitransplant immune responses. Type I interferon signaling plays an important role in the pro-rejection effect mediated by Toll-like receptor agonists and some bacteria. Similar pathways, however, in neonates can result in inhibition rather than activation of alloimmune responses. SUMMARY: The consequences of Toll-like receptor engagement by endogenous and exogenous ligands in transplantation may depend on the relative induction of inflammatory and regulatory pathways and the stage of development of the immune system.
PURPOSE OF REVIEW: This review summarizes recent advances in the role of endogenous and exogenous Toll-like receptor ligands in the activation and inhibition of immune responses in transplantation. RECENT FINDINGS: During an alloresponse, Toll-like receptors can be engaged by both damage-induced endogenous ligands or microbial-associated molecular patterns. The damage-induced molecule high mobility group box 1 protein and its binding to Toll-like receptor 4 have been identified as major initiators of antitumor and antitransplant immune responses. Type I interferon signaling plays an important role in the pro-rejection effect mediated by Toll-like receptor agonists and some bacteria. Similar pathways, however, in neonates can result in inhibition rather than activation of alloimmune responses. SUMMARY: The consequences of Toll-like receptor engagement by endogenous and exogenous ligands in transplantation may depend on the relative induction of inflammatory and regulatory pathways and the stage of development of the immune system.
Authors: Koichi Kobayashi; Lorraine D Hernandez; Jorge E Galán; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell Journal: Cell Date: 2002-07-26 Impact factor: 41.582
Authors: Ahmet H Elmaagacli; Michael Koldehoff; Heidrun Hindahl; Nina K Steckel; Rudolf Trenschel; Rudolf Peceny; Hellmut Ottinger; Peter-Michael Rath; Rudolf Stefan Ross; Michael Roggendorf; Hans Grosse-Wilde; Dietrich W Beelen Journal: Transplantation Date: 2006-01-27 Impact factor: 4.939
Authors: A Moreno; C Cervera; J Gavaldá; M Rovira; R de la Cámara; I Jarque; M Montejo; J de la Torre-Cisneros; J Miguel Cisneros; J Fortún; F López-Medrano; M Gurguí; P Muñoz; A Ramos; J Carratalá Journal: Am J Transplant Date: 2007-09-14 Impact factor: 8.086
Authors: Norimasa Ito; Richard A DeMarco; Robbie B Mailliard; Jie Han; Hannah Rabinowich; Pawel Kalinski; Donna Beer Stolz; Herbert J Zeh; Michael T Lotze Journal: J Leukoc Biol Date: 2006-09-12 Impact factor: 4.962
Authors: Roger P M Sutmuller; Martijn H M G M den Brok; Matthijs Kramer; Erik J Bennink; Liza W J Toonen; Bart-Jan Kullberg; Leo A Joosten; Shizuo Akira; Mihai G Netea; Gosse J Adema Journal: J Clin Invest Date: 2006-01-19 Impact factor: 14.808
Authors: Christopher A Adin; Zachary C VanGundy; Tracey L Papenfuss; Feng Xu; Mostafa Ghanem; Jonathan Lakey; Gregg A Hadley Journal: Cell Transplant Date: 2016-07-07 Impact factor: 4.064
Authors: Giorgio Raimondi; Tina L Sumpter; Benjamin M Matta; Mahesh Pillai; Natasha Corbitt; Yoram Vodovotz; Zhiliang Wang; Angus W Thomson Journal: J Immunol Date: 2009-12-09 Impact factor: 5.422
Authors: Jasper Iske; Yeqi Nian; Ryoichi Maenosono; Max Maurer; Igor M Sauer; Stefan G Tullius Journal: Cell Mol Immunol Date: 2019-03-06 Impact factor: 11.530